Table 2.

Demographics, and Clinical and Immunological Responses for Each Patient

Cohort	ID	Gender	Age	Tumor Type	Tumor Size	Previous Tx	# of Vac	IFN-γ ELISPOT					PFS	Dx to 1st V	OS
								IL13Rα2	EphA2	WT1	Sur	Tet
1
	1	M	42	OA	774	None	3	NA	NA	NA	NA	NA	3	7	14
	2	F	29	A	1960	None	12	40	54	39	2	NA	17	6	57
	3	M	47	A	4085	None	10	82	322	419	350	186	14	3	25
	4	F	34	A	3361	None	8	288	359	262	196	0	10	2	>50
	5	M	31	A	121	None	7	180	119	271	49	474	>47	11	>58
	6	M	57	A	5780	None	11	145	236	144	112	77	17	2	>48
	7	M	35	A	1972	None	9	0	533	377	69	90	14	4	33
	8	M	49	A	241	None	12	20	5	4	7	267	19	10	>48
	9	F	38	A	496	None	14	189	118	120	132	461	>42	4	>46
	10	M	51	OA	1136	None	14	41	342	700	125	151	>37	10	>47
	11	M	39	OA	1836	None	12	304	193	285	116	69	19	5	43
	12	F	30	OA	2520	None	8	51	514	253	81	56	11	2	>29
2	1	F	26	A	1782	RT	14	21	128.5	40	5	NA	>45	22	>67
3
	1	F	49	A	5344	None	10	6	0	8	3	0	11	26	>88
	2	F	44	A	1512	RT	3	NA	NA	NA	NA	NA	2	44	57
	3	M	36	OA	1236	BCNU & TMZ	10	82	210	47	450	337	12	66	96
	4	F	28	OA	3522	None	11	38	30	19	21	31	13	65	>110
	5	M	35	OA	1154	TMZ	8	6	32	18	14	23	6	36	74
	6	F	49	OA	442	None	8	97	707	109	50	41	6	52	>96
	7	F	38	O	1591	None	10	24	14	43	354	31	12	17	>60
	8	M	26	O	1591	None	8	0	27	9	0	5	>41	11	>52
	9	F	39	O	4489	None	11	13	97	203	134	0	16	57	>93
	10	M	49	OA	226	TMZ & RAD001	14	10	230	9	0	28	29	132	>164